Plasma revenues are estimated to account for approximately 78% of total revenue, while pharma revenue is estimated to account for approximately 20% of total revenue. Full year gross profit margins are expected to be between 54% 55%, reflecting increased revenue contribution from our patient affordability business. Operating expenses are expected to be between $30,000,000 $32,000,000 as we continue to make investments in people and technology to support the growth of our business. Of this amount, depreciation and amortization are expected to remain unchanged between $6,000,000 $6,500,000 while stock based compensation is expected to remain unchanged between $2,700,000 $3,000,000 Given the continued increases in our average daily balances of unrestricted and restricted cash, the current interest and the current interest rate environment, we expect to generate interest income of $3,000,000 to $3,200,000 We expect our tax rate to be between 28% 29% and our fully diluted share count outstanding to be 55,800,000 to 56 point 0,000,000 shares. Taking all of the factors above in consideration, we expect net income to be in the range of $2,000,000 to $3,000,000 or $0.04 to $0.06 per diluted share and adjusted EBITDA to be in the range of $9,000,000 to $10,000,000 which is 15% to 17% of total revenues or $0.16 to $0.18 per diluted share.